Skip to main content
. 2022 May 25;8(6):e09538. doi: 10.1016/j.heliyon.2022.e09538

Table 4.

Clinical response according to mREFLECT eligibility criteria.

Group1 (n = 54) Group2 (n = 85) χ2 P value
ORR 21/54 (38.90%) 21/85 (24.70%) 3.150 0.076
DCR 50/54 (92.60%) 63/85 (74.10%) 7.412 0.006

Group1, lenvatinib plus sintilimab treatment group; Group2, lenvatinib monotherapy group.

Objective response rate (ORR); Disease Control Rate (DCR).